Ftse Mib
33.641,96
-0,28%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
62.774,05
6,18%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NeuroBo Pharmaceuticals Inc (NRBO) NeuroBo Pharmaceuticals Inc (NRBO) Notizie

NRBO

NeuroBo Pharmaceuticals (NRBO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NRBO
DataOraFonteTitoloSimboloCompagnia
30/04/202414:01PR Newswire (US)NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
17/04/202414:05PR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/04/202414:01PR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
28/03/202413:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/03/202413:01PR Newswire (US)NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/03/202414:01PR Newswire (US)NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/03/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
29/02/202414:01PR Newswire (US)NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
12/02/202414:01PR Newswire (US)NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/02/202414:01PR Newswire (US)NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/01/202414:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
09/01/202414:30PR Newswire (US)NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/01/202414:01PR Newswire (US)NeuroBo to Participate in Industry and Investor Conferences in JanuaryNASDAQ:NRBONeuroBo Pharmaceuticals Inc
28/12/202314:45PR Newswire (US)NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
19/12/202314:43PR Newswire (US)NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/12/202314:31PR Newswire (US)NeuroBo to Participate in Investor Conferences in DecemberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/11/202322:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/11/202322:05PR Newswire (US)NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/11/202314:05PR Newswire (US)NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.NASDAQ:NRBONeuroBo Pharmaceuticals Inc
17/10/202314:01PR Newswire (US)NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
15/09/202314:01PR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202322:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202314:01PR Newswire (US)NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENTNASDAQ:NRBONeuroBo Pharmaceuticals Inc
09/08/202322:05PR Newswire (US)NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/08/202314:01PR Newswire (US)NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/08/202314:01PR Newswire (US)NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01NASDAQ:NRBONeuroBo Pharmaceuticals Inc
28/07/202312:02Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
29/06/202314:37Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NRBONeuroBo Pharmaceuticals Inc
27/06/202314:01PR Newswire (US)NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical ModelsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/06/202314:01PR Newswire (US)NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific SessionsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NRBO

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network